(2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells.Dr. Lager, Angela M Corradin, Olivia G Cregg, Jared M et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Patel, Rutulkumar Zhang, Luchang Desai, Amar et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Cancer Epidemiol 53:56-64Ĭhen, Lechuang Feng, Zhimin Yue, Hong et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Hum Mutat 39:1092-1101Īugestad, Knut M Keller, Deborah S Bakaki, Paul M et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Tissue Eng Part A 24:1831-1843Įvans, Daniel R Venkitachalam, Srividya Revoredo, Leslie et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Lennon, Donald Solchaga, Luis A Somoza, Rodrigo A et al. Int J Cardiol 273:168-176Įnane, Francis O Saunthararajah, Yogen Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Li, Jiayang Gresham, Kenneth S Mamidi, Ranganath et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Cancer Discov :īelur Nagaraj, Anil Joseph, Peronne Kovalenko, Olga et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Liu, Xia Taftaf, Rokana Kawaguchi, Madoka et al. The HSC Core Facility is planning to implement real time measurement of absolute numbers of CD34+ cells using IMGN2000 device and clinical scale G-CSF mobilized peripheral blood collections from normal donors for preclinical and basic research purposes. The HSC Core Facility also maintains a variety of murine and human hematopoietic cytokines and provides consultation to investigators working with hematopoietic cells. The facility routinely performs 14 day CFU-GM, BFU-E, CFU-GEMM, and CFU megakarocytic progenitor assays, Long-Term (5-week) Culture Initiating Cell (LTC-IC) assay, separation of mononuclear cells by density gradient (Ficoll-Hypaque or Percoll), adherence depletion of mononuclear cells, CD34+ cell enrichment with VarioMACS system, and mesenchymal stem cell culture purification. The HSC Core collects, processes, and distributes peripheral blood, bone marrow and umbilical cord blood samples from normal donors and patients according to an IRB approved protocol. The facility serves as a quality control/assurance laboratory for translational clinical trials of blood and marrow transplantation, 2) to procure and distribute human blood and marrow cells so as to promote translational research efforts in hematopoiesis and for biochemical endpoints within the Developmental Therapeutics Program. The HSC Core objectives are 1) to provide standard assays of hematopoiesis and specifically stem cell analysis for evolution of reconstitution after transplantation. The Hematopoietic Stem Cell Core Facility (HSC Core) serves as a resource for procurement and processing of human hematopoietic cells derived from a variety of sources, and routine phenotypic and functional characterization of these cells for the members of the Cancer Center.
0 Comments
Leave a Reply. |